{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:04:45Z","timestamp":1784120685975,"version":"3.55.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82160775"],"award-info":[{"award-number":["82160775"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","award":["2025GXNSFAA069334"],"award-info":[{"award-number":["2025GXNSFAA069334"]}],"id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangxi Higher Education Institutions Young and Middle-Aged Teachers' Basic Scientific Research Capacity Enhancement Program","award":["2025KY0382"],"award-info":[{"award-number":["2025KY0382"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12340-6","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:12:30Z","timestamp":1784117550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapeutic strategies for castration-resistant prostate cancer: A systematic review of mechanisms, clinical advances and emerging approaches"],"prefix":"10.1007","volume":"53","author":[{"given":"Zedong","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9884-994X","authenticated-orcid":false,"given":"Xueni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"12340_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"12340_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3892\/mco.2025.2826","volume":"22","author":"K Hashimoto","year":"2025","unstructured":"Hashimoto K, Nishimura S, Goto K (2025) PD\u20131\/PD\u2013L1 immune checkpoint in bone and soft tissue tumors (Review). Mol Clin Oncol 22:31. https:\/\/doi.org\/10.3892\/mco.2025.2826","journal-title":"Mol Clin Oncol"},{"key":"12340_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P et al (2024) Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer 23:108. https:\/\/doi.org\/10.1186\/s12943-024-02023-w","journal-title":"Mol Cancer"},{"key":"12340_CR4","doi-asserted-by":"publisher","first-page":"1869389","DOI":"10.1080\/2162402x.2020.1869389","volume":"10","author":"F Kast","year":"2021","unstructured":"Kast F, Klein C, Uma\u00f1a P, Gros A, Gasser S (2021) Advances in identification and selection of personalized neoantigen\/T-cell pairs for autologous adoptive T cell therapies. Oncoimmunology 10:1869389. https:\/\/doi.org\/10.1080\/2162402x.2020.1869389","journal-title":"Oncoimmunology"},{"key":"12340_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J et al (2018) Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 378:439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"key":"12340_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"12340_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00345-024-05341-2","volume":"30","author":"Y Niu","year":"2025","unstructured":"Wenzel M, Hoeh B, Humke C et al (2024) Influence of metastatic sites and burden on oncological outcomes in patients progressing to metastatic castration resistant prostate cancer. World J Urol 42:615. https:\/\/doi.org\/10.1007\/s00345-024-05341-2","journal-title":"J Mod Urol"},{"key":"12340_CR8","doi-asserted-by":"publisher","unstructured":"Menon S, Shin S, Dy G (2016) Advances in cancer immunotherapy in solid tumors. Cancers (Basel) 8:106. https:\/\/doi.org\/10.3390\/cancers8120106","DOI":"10.3390\/cancers8120106"},{"key":"12340_CR9","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.7150\/thno.100555","volume":"14","author":"SB Hansen","year":"2024","unstructured":"Hansen SB, Unal B, Kuzu OF, Saatcioglu F (2024) Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management. Theranostics 14:6913\u20136934. https:\/\/doi.org\/10.7150\/thno.100555","journal-title":"Theranostics"},{"key":"12340_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411\u2013422. https:\/\/doi.org\/10.1056\/NEJMoa1001294","journal-title":"N Engl J Med"},{"key":"12340_CR11","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509\u20132520. https:\/\/doi.org\/10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"key":"12340_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/2162402X.2019.1644109","volume":"22","author":"Y Wang","year":"2024","unstructured":"Taghizadeh H, Marhold M, Tomasich E et al (2019) Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives. Oncoimmunology. 8:e1644109. https:\/\/doi.org\/10.1080\/2162402X.2019.1644109","journal-title":"Oncol Progress"},{"key":"12340_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1158\/1078-0432.CCR-17-0019","volume":"46","author":"L Dong","year":"2023","unstructured":"Bilusic M, Madan RA, Gulley JL (2017) Immunotherapy of Prostate Cancer: Facts and Hopes. Clin Cancer Res. 23:6764-6770. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0019","journal-title":"Shanghai Med J"},{"key":"12340_CR14","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung IY et al (2022) PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 28:724\u2013734. https:\/\/doi.org\/10.1038\/s41591-022-01726-1","journal-title":"Nat Med"},{"key":"12340_CR15","doi-asserted-by":"publisher","first-page":"e1380764","DOI":"10.1080\/2162402x.2017.1380764","volume":"7","author":"SJ Priceman","year":"2018","unstructured":"Priceman SJ, Gerdts EA, Tilakawardane D et al (2018) Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Oncoimmunology 7:e1380764. https:\/\/doi.org\/10.1080\/2162402x.2017.1380764","journal-title":"Oncoimmunology"},{"key":"12340_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.intimp.2024.113137","volume":"33","author":"K Wang","year":"2025","unstructured":"Gu Q, Qi A, Wang N et al (2024) Unlocking Immunity: Innovative prostate cancer vaccine strategies. Int Immunopharmacol. 142:113137. https:\/\/doi.org\/10.1016\/j.intimp.2024.113137","journal-title":"J Clin Surg"},{"key":"12340_CR17","doi-asserted-by":"publisher","first-page":"189068","DOI":"10.1016\/j.bbcan.2023.189068","volume":"1879","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yan Q, Zeng Z, Fan C, Xiong W (2024) Advances and prospects of mRNA vaccines in cancer immunotherapy. Biochim Biophys Acta Rev Cancer 1879:189068. https:\/\/doi.org\/10.1016\/j.bbcan.2023.189068","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"12340_CR18","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/jmv.29748","volume":"26","author":"H Zhao","year":"2020","unstructured":"Anjum S, Naseer F, Ahmad T et al (2024) Co-delivery of oncolytic virus and chemotherapeutic modality: Vincristine against prostate cancer treatment: A potent viro-chemotherapeutic approach. J Med Virol 96:e29748. https:\/\/doi.org\/10.1002\/jmv.29748","journal-title":"Med Recapitulate"},{"key":"12340_CR19","doi-asserted-by":"publisher","first-page":"100037","DOI":"10.1016\/j.pscia.2024.100037","volume":"2","author":"Y Chen","year":"2024","unstructured":"Chen Y, Tao M, Wu X et al (2024) Current status and research progress of oncolytic virus. Pharm Sci Adv 2:100037. https:\/\/doi.org\/10.1016\/j.pscia.2024.100037","journal-title":"Pharm Sci Adv"},{"key":"12340_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12032-020-01417-2","volume":"37","author":"L Han","year":"2020","unstructured":"Han L, Mei J, Ma J et al (2020) Cinnamaldehyde induces endogenous apoptosis of the prostate cancer-associated fibroblasts via interfering the Glutathione-associated mitochondria function. Med Oncol 37:91. https:\/\/doi.org\/10.1007\/s12032-020-01417-2","journal-title":"Med Oncol"},{"key":"12340_CR21","doi-asserted-by":"publisher","first-page":"101041","DOI":"10.1016\/j.drup.2023.101041","volume":"73","author":"H Wang","year":"2024","unstructured":"Wang H, Wang X, Zhang X, Xu W (2024) The promising role of tumor-associated macrophages in the treatment of cancer. Drug Resist Updat 73:101041. https:\/\/doi.org\/10.1016\/j.drup.2023.101041","journal-title":"Drug Resist Updat"},{"key":"12340_CR22","doi-asserted-by":"publisher","unstructured":"Fan T, Zhang M, Yang J et al ( 2023) Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther 8:450. https:\/\/doi.org\/10.1038\/s41392-023-01674-3","DOI":"10.1038\/s41392-023-01674-3"},{"key":"12340_CR23","doi-asserted-by":"publisher","unstructured":"Bilusic M, McMahon S, Madan RA et al (2021) Phase I study of a multitargeted recombinant Ad5 PSA\/MUC-1\/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer 9:e002374. https:\/\/doi.org\/10.1136\/jitc-2021-002374","DOI":"10.1136\/jitc-2021-002374"},{"key":"12340_CR24","doi-asserted-by":"publisher","first-page":"5162","DOI":"10.1158\/1078-0432.Ccr-20-0945","volume":"26","author":"CE Kyriakopoulos","year":"2020","unstructured":"Kyriakopoulos CE, Eickhoff JC, Ferrari AC et al (2020) Multicenter phase i trial of a DNA vaccine encoding the androgen receptor ligand-binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer. Clin Cancer Res 26:5162\u20135171. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-0945","journal-title":"Clin Cancer Res"},{"key":"12340_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3892\/or.2020.7847","volume":"45","author":"M Noguchi","year":"2021","unstructured":"Noguchi M, Fujimoto K, Arai G et al (2021) A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel. Oncol Rep 45:159\u2013168. https:\/\/doi.org\/10.3892\/or.2020.7847","journal-title":"Oncol Rep"},{"key":"12340_CR26","doi-asserted-by":"publisher","unstructured":"Autio KA, Higano CS, Nordquist L et al (2023) First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer 11:e005702. https:\/\/doi.org\/10.1136\/jitc-2022-005702","DOI":"10.1136\/jitc-2022-005702"},{"key":"12340_CR27","doi-asserted-by":"publisher","unstructured":"Cappuccini F, Bryant R, Pollock E et al (2020) Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. J Immunother Cancer 8:e000928. https:\/\/doi.org\/10.1136\/jitc-2020-000928","DOI":"10.1136\/jitc-2020-000928"},{"key":"12340_CR28","doi-asserted-by":"publisher","unstructured":"Passariello M, Manna L, Lembo RR et al (2025) Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics. Cell Death Discovery 11:58 . https:\/\/doi.org\/10.1038\/s41420-025-02329-8","DOI":"10.1038\/s41420-025-02329-8"},{"key":"12340_CR29","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.intimp.2020.106700","volume":"39","author":"W Huang","year":"2023","unstructured":"Tang S, Ning Q, Yang L et al (2020) Mechanisms of immune escape in the cancer immune cycle. Int Immunopharmacol. 86:106700. https:\/\/doi.org\/10.1016\/j.intimp.2020.106700","journal-title":"J Practical Med"},{"key":"12340_CR30","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1186\/s12943-024-02023-w","volume":"36","author":"R Song","year":"2020","unstructured":"Lin X, Kang K, Chen P et al (2024). Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 23:108. https:\/\/doi.org\/10.1186\/s12943-024-02023-w","journal-title":"J Practical Med"},{"key":"12340_CR31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.Cd-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP (2018) Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov 8:1069\u20131086. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0367","journal-title":"Cancer Discov"},{"key":"12340_CR32","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1158\/1078-0432.Ccr-20-1981","volume":"27","author":"DP Petrylak","year":"2021","unstructured":"Petrylak DP, Loriot Y, Shaffer DR et al (2021) Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Clin Cancer Res 27:3360\u20133369. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-1981","journal-title":"Clin Cancer Res"},{"key":"12340_CR33","doi-asserted-by":"publisher","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M et al (2020) Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 38:395\u2013405. https:\/\/doi.org\/10.1200\/jco.19.01638","DOI":"10.1200\/jco.19.01638"},{"key":"12340_CR34","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1158\/1078-0432.Ccr-24-1595","volume":"30","author":"PI Velho","year":"2024","unstructured":"Velho PI, Bastos DA, Saint\u2019ana PT et al (2024) Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects. Clin Cancer Res 30:5342\u20135352. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1595","journal-title":"Clin Cancer Res"},{"key":"12340_CR35","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1096\/fj.202501308RR","volume":"43","author":"Y Qiu","year":"2024","unstructured":"Wang Y, Cao F, Huang M et al (2025) Mapping a New Blueprint of Multimodal Immunotherapy Against Prostate Cancer: Breakthroughs, Barriers, and Bold Frontiers. FASEB J. 39:e70989. https:\/\/doi.org\/10.1096\/fj.202501308RR","journal-title":"J Pharm Res"},{"key":"12340_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41416-022-01991-4","volume":"128","author":"A Rodriguez-Vida","year":"2023","unstructured":"Rodriguez-Vida A, Maroto P, Font A et al (2023) Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. Br J Cancer 128:21\u201329. https:\/\/doi.org\/10.1038\/s41416-022-01991-4","journal-title":"Br J Cancer"},{"key":"12340_CR37","doi-asserted-by":"publisher","unstructured":"Petrylak DP, Ratta R, Matsubara N et al (2025) Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, Phase III KEYNOTE-921 Trial. J Clin Oncol 43:1638\u20131649. https:\/\/doi.org\/10.1200\/jco-24-01283","DOI":"10.1200\/jco-24-01283"},{"key":"12340_CR38","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/jco.23.00233","volume":"41","author":"ES Antonarakis","year":"2023","unstructured":"Antonarakis ES, Park SH, Goh JC et al (2023) Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. J Clin Oncol 41:3839\u20133850. https:\/\/doi.org\/10.1200\/jco.23.00233","journal-title":"J Clin Oncol"},{"key":"12340_CR39","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00262-020-02498-8","volume":"69","author":"M Noguchi","year":"2020","unstructured":"Noguchi M, Arai G, Egawa S et al (2020) Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial. Cancer Immunol Immunotherapy 69:847\u2013857. https:\/\/doi.org\/10.1007\/s00262-020-02498-8","journal-title":"Cancer Immunol Immunotherapy"},{"key":"12340_CR40","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","volume":"28","author":"T Powles","year":"2022","unstructured":"Powles T, Yuen KC, Gillessen S et al (2022) Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med 28:144\u2013. https:\/\/doi.org\/10.1038\/s41591-021-01600-6","journal-title":"Nat Med"},{"key":"12340_CR41","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41391-024-00865-5","volume":"28","author":"JN Graff","year":"2025","unstructured":"Graff JN, Hoimes CJ, Gerritsen WR et al (2025) Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study. Prostate Cancer Prostatic Dis 28:411\u2013418. https:\/\/doi.org\/10.1038\/s41391-024-00865-5","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"12340_CR42","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s10637-024-01482-8","volume":"42","author":"EI Heath","year":"2024","unstructured":"Heath EI, Chen W, Choi JE et al (2024) Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer. Investig New Drugs 42:675\u2013684. https:\/\/doi.org\/10.1007\/s10637-024-01482-8","journal-title":"Investig New Drugs"},{"key":"12340_CR43","doi-asserted-by":"publisher","unstructured":"Fizazi K, Retz M, Petrylak DP et al (2022) Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. J Immunother Cancer 10:e004761. https:\/\/doi.org\/10.1136\/jitc-2022-004761","DOI":"10.1136\/jitc-2022-004761"},{"key":"12340_CR44","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/s1470-2045(22)00278-9","volume":"23","author":"N Agarwal","year":"2022","unstructured":"Agarwal N, McGregor B, Maughan BL et al (2022) Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol 23:899\u2013909. https:\/\/doi.org\/10.1016\/s1470-2045(22)00278-9","journal-title":"Lancet Oncol"},{"key":"12340_CR45","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2217\/fon-2021-1096","volume":"18","author":"N Agarwal","year":"2022","unstructured":"Agarwal N, Azad A, Carles J et al (2022) A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol 18:1185\u20131198. https:\/\/doi.org\/10.2217\/fon-2021-1096","journal-title":"Future Oncol"},{"key":"12340_CR46","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","volume":"38","author":"P Sharma","year":"2020","unstructured":"Sharma P, Pachynski RK, Narayan V et al (2020) Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell 38:489\u2013499.e3. https:\/\/doi.org\/10.1016\/j.ccell.2020.08.007","journal-title":"Cancer Cell"},{"key":"12340_CR47","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1158\/1078-0432.Ccr-24-0400","volume":"30","author":"CB Nguyen","year":"2024","unstructured":"Nguyen CB, Reimers MA, Perera C et al (2024) Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial. Clin Cancer Res 30:3200\u20133210. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-0400","journal-title":"Clin Cancer Res"},{"key":"12340_CR48","doi-asserted-by":"publisher","unstructured":"Rawat K, Punia V, Mathews P et al (2025) Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer. J Immunother Cancer 13:e012690. https:\/\/doi.org\/10.1136\/jitc-2025-012690","DOI":"10.1136\/jitc-2025-012690"},{"key":"12340_CR49","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41585-019-0251-x","volume":"16","author":"MJ Morris","year":"2019","unstructured":"Morris MJ, Corey E, Guise TA et al (2019) Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol 16:745\u2013756. https:\/\/doi.org\/10.1038\/s41585-019-0251-x","journal-title":"Nat Rev Urol"},{"key":"12340_CR50","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1158\/1078-0432.Ccr-20-4476","volume":"27","author":"CH Marshall","year":"2021","unstructured":"Marshall CH, Fu W, Wang H et al (2021) Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clin Cancer Res 27:1623\u20131630. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-4476","journal-title":"Clin Cancer Res"},{"key":"12340_CR51","doi-asserted-by":"publisher","unstructured":"Dorff T, Hirasawa Y, Acoba J et al (2021) Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. J Immunother Cancer 9:e002931. https:\/\/doi.org\/10.1136\/jitc-2021-002931","DOI":"10.1136\/jitc-2021-002931"},{"key":"12340_CR52","doi-asserted-by":"publisher","unstructured":"Hannan R, Dohopolski MJ, Pop LM et al (2022) Phase II trial of sipuleucel-t and stereotactic ablative body radiation for patients with metastatic castrate-resistant prostate cancer. Biomedicines 10:1419. https:\/\/doi.org\/10.3390\/biomedicines10061419","DOI":"10.3390\/biomedicines10061419"},{"key":"12340_CR53","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2021.08.011","volume":"81","author":"EM Kwan","year":"2022","unstructured":"Kwan EM, Spain L, Anton A et al (2022) Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial. Eur Urol 81:253\u2013262. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.011","journal-title":"Eur Urol"},{"key":"12340_CR54","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1093\/oncolo\/oyac048","volume":"27","author":"MN Stein","year":"2022","unstructured":"Stein MN, Fong L, Tutrone R et al (2022) ADXS31142 Immunotherapy\u2009\u00b1\u2009Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I\/II KEYNOTE-046 Study. Oncologist 27:453\u2013461. https:\/\/doi.org\/10.1093\/oncolo\/oyac048","journal-title":"Oncologist"},{"key":"12340_CR55","doi-asserted-by":"publisher","unstructured":"McNeel DG, Eickhoff JC, Wargowski E et al (2022) Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). J Immunother Cancer 10:1419. https:\/\/doi.org\/10.1136\/jitc-2021-004198","DOI":"10.1136\/jitc-2021-004198"},{"key":"12340_CR56","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1158\/1078-0432.Ccr-22-1601","volume":"29","author":"UN Vaishampayan","year":"2023","unstructured":"Vaishampayan UN, Thakur A, Chen W et al (2023) Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 29:122\u2013133. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-1601","journal-title":"Clin Cancer Res"},{"key":"12340_CR57","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s00262-023-03421-7","volume":"72","author":"LCV Thomsen","year":"2023","unstructured":"Thomsen LCV, Honor\u00e9 A, Reis\u00e6ter LAR et al (2023) A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother. 72:2357\u20132373. https:\/\/doi.org\/10.1007\/s00262-023-03421-7","journal-title":"Cancer Immunol Immunotherapy"},{"key":"12340_CR58","doi-asserted-by":"publisher","first-page":"188625","DOI":"10.1016\/j.bbcan.2021.188625","volume":"1876","author":"MY Konoshenko","year":"2021","unstructured":"Konoshenko MY, Bryzgunova OE, Laktionov PP (2021) miRNAs and androgen deprivation therapy for prostate cancer. Biochim Biophys Acta Rev Cancer 1876:188625. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188625","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"12340_CR59","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fonc.2023.1240864","volume":"51","author":"S Yang","year":"2022","unstructured":"Leaning D, Kaur G, Morgans AK et al (2023) Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews. Front Oncol 13:1240864. https:\/\/doi.org\/10.3389\/fonc.2023.1240864","journal-title":"J Med Res"},{"key":"12340_CR60","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s40364-021-00294-9","volume":"42","author":"J Zhang","year":"2025","unstructured":"Zhou S, Liu M, Ren F et al (2021) The landscape of bispecific T cell engager in cancer treatment. Biomark Res 9:38. https:\/\/doi.org\/10.1186\/s40364-021-00294-9","journal-title":"J Shenyang Pharm Univ"},{"key":"12340_CR61","doi-asserted-by":"publisher","unstructured":"Rosenblum D, Joshi N, Tao W, Karp JM, Peer D (2018) Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun 9:1410. https:\/\/doi.org\/10.1038\/s41467-018-03705-y","DOI":"10.1038\/s41467-018-03705-y"},{"key":"12340_CR62","doi-asserted-by":"publisher","unstructured":"Xu WT, Yang Z, Lu NH (2016) Molecular targeted therapy for the treatment of gastric cancer. J Experimental Clin Cancer Res 35:1. https:\/\/doi.org\/10.1186\/s13046-015-0276-9","DOI":"10.1186\/s13046-015-0276-9"},{"key":"12340_CR63","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1158\/1078-0432.Ccr-23-2978","volume":"30","author":"T Dorff","year":"2024","unstructured":"Dorff T, Horvath LG, Autio K et al (2024) A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 30:1488\u20131500. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-2978","journal-title":"Clin Cancer Res"},{"key":"12340_CR64","doi-asserted-by":"publisher","unstructured":"Aggarwal RR, Vuky J, Vanderweele D et al (2025) Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 43:1824\u20131834. https:\/\/doi.org\/10.1200\/jco-24-01989","DOI":"10.1200\/jco-24-01989"},{"key":"12340_CR65","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41391-021-00402-8","volume":"25","author":"CG Drake","year":"2022","unstructured":"Drake CG, Pachynski RK, Subudhi SK et al (2022) Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 25:219\u2013228. https:\/\/doi.org\/10.1038\/s41391-021-00402-8","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"12340_CR66","doi-asserted-by":"publisher","unstructured":"Calvo E, Doger B, Carles J et al (2025) A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer. Oncologist 30:oyae313. https:\/\/doi.org\/10.1093\/oncolo\/oyae313","DOI":"10.1093\/oncolo\/oyae313"},{"key":"12340_CR67","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","volume":"30","author":"TB Dorff","year":"2024","unstructured":"Dorff TB, Blanchard MS, Adkins LN et al (2024) PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 30:1636\u20131644. https:\/\/doi.org\/10.1038\/s41591-024-02979-8","journal-title":"Nat Med"},{"key":"12340_CR68","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1200\/jco-25-00678","volume":"43","author":"MN Stein","year":"2025","unstructured":"Stein MN, Vinceneux A, Robbrecht D et al (2025) Pasritamig, a first-in-class, bispecific t-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: a phase i study. J Clin Oncol 43:2515\u20132526. https:\/\/doi.org\/10.1200\/jco-25-00678","journal-title":"J Clin Oncol"},{"key":"12340_CR69","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.Cd-23-0964","volume":"14","author":"WK Kelly","year":"2024","unstructured":"Kelly WK, Danila DC, Lin CC et al (2024) Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2\u2009+\u20091 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study. Cancer Discov 14:76\u201389. https:\/\/doi.org\/10.1158\/2159-8290.Cd-23-0964","journal-title":"Cancer Discov"},{"key":"12340_CR70","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/pros.23988","volume":"80","author":"M Tang","year":"2020","unstructured":"Tang M, Gao SL, Zhang L et al (2020) Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals. Prostate 80:742\u2013752. https:\/\/doi.org\/10.1002\/pros.23988","journal-title":"Prostate"},{"key":"12340_CR71","doi-asserted-by":"publisher","unstructured":"Zhu YN, Zhao Y, Wen JL et al (2023) Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer. Sci Immunol 8:eade4656. https:\/\/doi.org\/10.1126\/sciimmunol.ade4656","DOI":"10.1126\/sciimmunol.ade4656"},{"key":"12340_CR72","doi-asserted-by":"publisher","unstructured":"Zhou XM, Cheng SL, Chen ZJ, Zhang JM, Wang JQ, Li Q (2025) Inhibiting HnRNP L-mediated alternative splicing of EIF4G1 counteracts immune checkpoint blockade resistance in Castration-resistant prostate Cancer. Neoplasia 60:101109. https:\/\/doi.org\/10.1016\/j.neo.2024.101109","DOI":"10.1016\/j.neo.2024.101109"},{"key":"12340_CR73","doi-asserted-by":"publisher","unstructured":"Wang FM, Xing NZ, Li JX (2025) Combined treatment with anti-PSMA antibody and human peripheral blood-derived NK cells for castration-resistant prostate cancer. Front Immunol 16:1572676. https:\/\/doi.org\/10.3389\/fimmu.2025.1572676","DOI":"10.3389\/fimmu.2025.1572676"},{"key":"12340_CR74","doi-asserted-by":"publisher","unstructured":"Deng B, Ke BH, Tian QX, Gao YK, Zhai QL, Zhang WQ (2024) Targeting AURKA with multifunctional nanoparticles in CRPC therapy. J Nanobiotechnol 22:803. https:\/\/doi.org\/10.1186\/s12951-024-03070-7","DOI":"10.1186\/s12951-024-03070-7"},{"key":"12340_CR75","doi-asserted-by":"publisher","unstructured":"Zheng XN, Xu H, Yi XY et al (2021) Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine. Mol Cancer 20:160. https:\/\/doi.org\/10.1186\/s12943-021-01452-1","DOI":"10.1186\/s12943-021-01452-1"},{"key":"12340_CR76","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/jco-24-01283","volume":"43","author":"DP Petrylak","year":"2025","unstructured":"Petrylak DP, Ratta R, Matsubara N et al (2025) Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial. J Clin Oncol 43:1638\u20131649. https:\/\/doi.org\/10.1200\/jco-24-01283","journal-title":"J Clin Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12340-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12340-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12340-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:12:32Z","timestamp":1784117552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12340-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12340"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12340-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Natural Science Foundation of Guangxi Zhuang Autonomous Region (2025GXNSFAA069334); the National Natural Science Foundation of China (82160775); the Guangxi Higher Education Institutions Young and Middle-Aged Teachers\u2019 Basic Scientific Research Capacity Enhancement Program (2025KY0382); the Outstanding Young Scholars Fund of Guangxi University of Chinese Medicine (2025JQ004).","order":2,"name":"Ethics","label":"Financial support and sponsorship","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1161"}}